• Explore /
  • Poster
  • / A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.

A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.

Abstract Poster

Authors

null

Paul G. Richardson

Dana-Farber Cancer Institute, Boston, MA

Paul G. Richardson , Michael Amatangelo , James R. Berenson , Claudio Cerchione , Meletios A. Dimopoulos , Charlotte Toftmann Hansen , Soo Jeong Hwang , Phillip Koo , Junya Kuroda , Albert Oriol , Robert Z. Orlowski , HANG QUACH , Marc S. Raab , Alberto Rocci , Yue Wang , Darrell White , Brian Yu , Zehua Zhou , Jessica Katz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT05552976

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS8070)

DOI

10.1200/JCO.2023.41.16_suppl.TPS8070

Abstract #

TPS8070

Poster Bd #

58b

Abstract Disclosures

Similar Posters

First Author: Sagar Lonial

First Author: Cyrille Touzeau

First Author: Krish Patel

Poster

2020 ASCO Virtual Scientific Program

Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).

Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).

First Author: Cristina Gasparetto